Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
64.50
+1.55 (2.46%)
Dec 20, 2024, 4:00 PM EST - Market closed
Disc Medicine Employees
Disc Medicine had 74 employees as of December 31, 2023. The number of employees increased by 28 or 60.87% compared to the previous year.
Employees
74
Change (1Y)
28
Growth (1Y)
60.87%
Revenue / Employee
n/a
Profits / Employee
-$1,398,365
Market Cap
1.92B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 74 | 28 | 60.87% |
| Dec 31, 2022 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| National HealthCare | 13,123 |
| UFP Technologies | 3,093 |
| Amphastar Pharmaceuticals | 1,761 |
| Galapagos NV | 1,123 |
| ImmunityBio | 628 |
| Recursion Pharmaceuticals | 500 |
| MannKind | 414 |
| Harmony Biosciences Holdings | 246 |
IRON News
- 12 days ago - Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 13 days ago - Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Disc Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. - GlobeNewsWire
- 6 weeks ago - Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval - GlobeNewsWire
- 7 weeks ago - Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) - GlobeNewsWire
- 2 months ago - Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week - GlobeNewsWire
- 2 months ago - Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week - GlobeNewsWire